Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the grant of an inducement award to the newly appointed Senior Vice President and Chief Legal Officer, Alejandra Carvajal. In connection with the appointment, the Compensation Committee of the Board of Directors of Mersana Therapeutics approved a stock option grant to Ms. Carvajal as an inducement material to Ms. Carvajal entering into employment with Mersana Therapeutics, in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option grant provides for the purchase of up to 112,500 shares of Mersana Therapeutics common stock, at a price of $16.98 per share, the closing price per share of Mersana Therapeutics common stock on the date of grant, and vests over four years, with 25% of the shares vesting on the first anniversary of the Ms. Carvajal’s employment start date, and the remainder vestng in equal quarterly installments over the following three years, subject to Ms. Carvajal’s continued employment with Mersana Therapeutics through such applicable vesting dates.
About Mersana Therapeutics
Investor & Media Contact
MSPs and the IT Skills Gap
OpenSIPIt - Bringing InterOp Testing to the heart of the Community